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POTENSI TERAPEUTIK SEL TUNJANG ENDOMETRIUM DARIPADA 
DARAH HAID TERHADAP MODEL PENYAKIT PARKINSON IN VITRO 
DAN IN VIVO 
ABSTRAK 
Sel stem endometrium yang diperolehi daripada darah haid manusia (MenSC) 
telah menunjuk potensi terapeutik terhadap pelbagai penyakit dari segi imunoregulasi 
dan regenerasi tisu. Walau bagaimanapun, kesannya terhadap penyakit Parkinson (PD) 
tidak diketahui. Kajian ini bertujuan untuk menilai fungsi perlindungan MenSC dan 
derivatifnya terhadap PD model in vitro dan in vivo. Sel neuroblastoma (SH-SY5Y) 
dan kepingan tengah otak didedahkan kepada 1-methyl-4-phenylpyridinium (MPP+) 
untuk membina PD model in vitro. Metil-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
telah digunakan untuk membina model mencit PD melalui suntikan intraperitoneal. 
Selepas ko-kultur dalam model PD vitro dengan medium MenSCs (MenSCs-CM), 
daya maju kepingan otak tengah telah diuji dengan menggunakan Prestoblue dan asai 
lactate dehydrogenase. Ekpresi gen-gen yang berkaitan dengan inflamasi, anti-oksidan 
dan apoptosis telah dikesan oleh qRT-PCR. Dihydroethidium, Rhodamine123, dan 
Annexin V/PI digunakan untuk mengesan spesies oksigen reaktif (ROS), potensi 
membran mitokondria, dan apoptosis sel. Array protein telah digunakan untuk 
menganalisis faktor yang terdapat dalam MenSCs-CM. Selain itu, MenSC telah 
dipindahkan ke bahagian striatum (Str) otak mencit PD dengan menggunakan alat 
stereotaxic. Masa kelangsungan tahap MenSC, dopamin (DA), ekspresi gen 
keradangan dan gen anti-oksidan telah dinilai. Kyoto Encyclopedia of Genes and 
Genomes (KEGG) digunakan untuk menganalisis laluannya. Keputusan menunjukkan 
MenSCs-CM mengurangkan neurotoksisiti MPP+ dengan mengawal ekspresi 
 xxii 
 
cytokines pro dan anti-radang, memulihkan potensi membran mitokondria, 
mengurangkan tekanan oksidatif, dan menghalang apoptosis sel. Kesan perlindungan 
MenSCs-CM kepada PD juga disahkan terhadap kepingan otak. Keputusan 
menunjukkan bahawa MenSCs-CM telah meningkatkan daya saing hidup sel secara 
signifikan disebabkan oleh sifat anti-radang dan anti-oksidan. Arus protein 
menunjukkan terdapat sekurang-kurangnya 12 jenis faktor neurotropik dalam 
MenSCs-CM, yang boleh menyumbang kepada fungsi perlindungan MenSCs-CM 
dalam merawat PD. Eksperimen in vivo menunjukkan bahawa MenSCs berhidup di 
dalam bahagian Str otak mencit selama 28 hari. MenSCs yang dipindahkan telah 
meningkatkan tahap dopamin di bahagian Str dan meninggikan ekspresi gen anti-
inflamasi (p <0.05 vs kumpulan PD + PBS). Di samping itu, MenSC meningkatkan 
ekspresi gen anti oksidan Nrf-2 dan gen aliran bawahnya (p <0.05 vs kumpulan PD + 
PBS). Analisis KEGG menunjukkan faktor-faktor yang dihasilkan oleh MenSCs 
terlibat dalam mekanisme PI3K/Akt, menerangkan sebahagian fungsi anti-oksidasi 
MenSC. Kajian ini membuktikan pertama kali bahawa MenSCs-CM dan MenSCs 
mempunyai kesan perlindungan terhadap model in vitro dan in vivo penyakit PD, 
justeru mencadangkan bahawa MenSCs berprospektif digunakan sebagai terapi sel 
atau tanpa sel bagi penyakit PD. 
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THERAPEUTIC POTENTIAL OF MENSTRUAL BLOOD-DERIVED 
ENDOMETRIUM STEM CELLS ON IN VITRO AND IN VIVO 
PARKINSON’S DISEASE MODELS 
ABSTRACT 
Human menstrual blood-derived endometrial stem cells (MenSCs) have shown 
therapeutic potential on various diseases by immunoregulation and tissue regeneration. 
However, their effects on Parkinson’s disease (PD) remain unknown. The aim of this 
study was to evaluate the protective function of MenSCs and their derivatives on in 
vitro and in vivo PD models. Neuroblastoma cell line (SH-SY5Y) and mouse midbrain 
slice were exposed to 1-methyl-4-phenylpyridinium (MPP+) to establish in vitro level 
PD models. Then, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was used to 
construct PD mouse model by intraperitoneal injection. After co-culture in vitro PD 
models with conditioned medium of MenSCs (MenSCs-CM), the viability of cell and 
midbrain slice were detected by Prestoblue and lactate dehydrogenase assay. The 
expression of inflammatory genes, anti-oxidant and apoptosis-related genes were 
detected by qRT-PCR. Dihydroethidium, Rhodamine123, and Annexin V/PI staining 
were used to detect reactive oxygen species (ROS), mitochondrial membrane potential, 
and cell apoptosis, respectively. Protein array was conducted to analyze factors inside 
MenSCs-CM. Moreover, MenSCs were transplanted to striatum (Str) region of PD 
mouse brain using a stereotaxic instrument. Survival time of MenSCs, dopamine (DA) 
level, expression of inflammatory genes and anti-oxidant genes were evaluated. Kyoto 
Encyclopedia of Genes and Genomes (KEGG) analysis was used to analyze pathways. 
Results showed MenSCs-CM attenuated MPP+-induced neurotoxicity by regulating 
 xxiv 
 
pro- and anti-inflammatory cytokines expression, restoring mitochondrial membrane 
potential, reducing oxidative stress, and inhibiting cell apoptosis. The protective effect 
of MenSCs-CM on PD was also confirmed on slice level. Results showed MenSCs-
CM significantly rescued midbrain slice viability reduction by anti-inflammatory and 
anti-oxidant properties (p<0.05 vs MPP+ + DMEM group). Protein array demonstrated 
there were at least 12 types of neurotrophic factors in MenSCs-CM, which may 
contribute to the protective function of MenSCs-CM in treating PD. In vivo 
experiments showed MenSCs survived in Str region of mouse brain for at least 28 days. 
Transplanted MenSCs significantly increased dopamine (DA) level in Str region and 
up-regulated the expression of anti-inflammatory genes (p<0.05 vs PD + PBS group). 
In addition, MenSCs increased the expression of anti-oxidant gene Nrf-2 and its down-
stream genes (p<0.05 vs PD + PBS group). KEGG analysis showed factors secreted 
by MenSCs were involved in PI3K/Akt pathway, which may partly explain the anti-
oxidant function of MenSCs. This study provided the first evidence that MenSCs-CM 
and MenSCs had protective effect on in vitro and in vivo PD models, suggesting 
MenSCs is a potential cell source used for cell-based or cell-free therapies in PD.
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CHAPTER 1 
GENERAL INTRODUCTION  
1.1 Introduction of Parkinson’s Disease (PD) 
1.1.1 Incidence, features, and clinical manifestations of PD 
Parkinson’s disease (PD) is named after James Parkinson, who first reported 
this disease in 1817 (Dauer and Przedborski, 2003). It is the second most common age-
related neurodegenerative disease, which is developed with mean age of 55 years old 
(Canet-Aviles et al., 2014). Its prevalence is 1%-2% for seniors above 65 years old and 
increased to almost 4% in seniors above 85 years old (Canet-Aviles et al., 2014).  
The major features of PD are dopaminergic neurons progressive loss in the 
substantia nigra pars compacta (SNc) of the brain and intracellular accumulation of 
Lewy bodies (Dezawa et al., 2001, Wolff et al., 2011). Because of dopaminergic 
neurons loss, SNc pigmentation is normally observed in PD patients (Dauer and 
Przedborski, 2003). The cell body of dopaminergic neurons is located in the SNc and 
the axon of dopaminergic neurons mainly project to the putamen area of the striatum 
(Str) (Dauer and Przedborski, 2003). The loss of dopaminergic neurons causes the 
decreasing number of dopamine (DA) transporter, and thus lead to DA depletion in 
putamen of Str (Dauer and Przedborski, 2003). Dopaminergic neurons are also 
distributed in ventral tegmental area (VTA), which is adjacent to SNc and mainly 
projects to the caudate of Str (Dauer and Przedborski, 2003). In PD patients, 
dopaminergic neurons loss is mainly occurred in SNc, while the neurons in VTA region 
are much less affected (Dauer and Przedborski, 2003). Consistently, DA depletion is 
not prominent in the caudate (Dauer and Przedborski, 2003).  
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Clinically, any disease involving Str damage or DA depletion may lead to 
parkinsonism syndromes. This disease is characterized by postural instability, resting 
tremor, hypokinesia, altered gait, muscular rigidity, and bradykinesia (Dauer and 
Przedborski, 2003, Joers and Emborg, 2009, Lindvall and Kokaia, 2010). PD accounts 
for about 80% parkinsonism cases. 95%-99% cases of PD are sporadic and the etiology 
is unknown. Usually, the risk factors include old age, head injury and exposure to 
environmental toxins, like herbicides and pesticides (Billingsley, et al., 2018). A small 
proportion of PD cases are familial, linking to genetic mutations (Billingsley, et al., 
2018).  
1.1.2 Pathogenesis of PD 
1.1.2(a) Cellular mechanisms 
Evidences suggest two major hypotheses related to the pathogenesis of PD 
(Schapira et al., 2007, Billingsley et al., 2018). One is misfolded intracellular α-
synuclein caused by several reasons. α-synuclein is encoded by gene SNCA and its 
mutation directly induces misfolded α-synuclein protein (Billingsley et al., 2018). 
Besides, mutations in the PARKIN or UCH-L1 genes can damage the ubiquitin-
proteasome system to detect and degrade the misfolded proteins (Setsuie and Wada, 
2007, Kasten et al., 2018). Furthermore, reactive oxygen/hydrogen species may 
increase the risk of generation abnormal conformation and oxidatively modified 
proteins (Subramaniam and Chesselet, 2013, Deweerdt et al., 2016). Misfolded α-
synuclein (α-syn) may directly cause cell damage or may aggregate inside the cells 
and then forms Lewy bodies (LBs) (Deweerdt, 2016). Controversy exists regarding 
the meaning of LBs formation (Shults et al., 2006, Wakabayashi et al., 2013). Some 
researchers reported LBs caused cell damage perhaps by disturbing substance 
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transportation in neurons and it may sequester proteins playing a crucial role in cell 
survival (Katsuse et al., 2003). LBs contributed to microtubule regression, 
mitochondria loss, and nuclear degradation in neurons of PD patients (Power et al., 
2017). Recasens et al. isolated LBs-enriched fractions from postmortem PD patients 
and transplanted into SN or Str region of wild type mice and monkeys, results showed 
the LBs fractions induced neurodegeneration on both mice and monkeys (Recasens et 
al., 2014). However, other researchers proposed that there was no correlation between 
protein deposition and the apoptosis of dopaminergic neurons (Markesbery et al., 2009, 
Parkkinen et al., 2011). Clinical study showed the distribution and density of LBs had 
no relationship with the severity of dopaminergic neurons loss (Parkkinen et al., 2011). 
Besides, LBs was also found in some elderly people without neurodegenerative disease 
(Markesbery et al., 2009). The inclusion formation may be a defensive process meant 
to remove soluble abnormal proteins and to prevent the misfolded protein to be 
involved in the organized metabolism of cells, which can protect cells from harmful 
effects of abnormal proteins (Shults et al., 2006, Wakabayashi et al., 2013).  
The interaction between α-Syn and monoamine oxidase type B (MAO-B) have 
been clarified recently (Zhang et al., 2017, Kang et al., 2018). MAO-B can catalyze 
the oxidative deamination of monoamine substances, such as DA, and produces 
aldehydes and H2O2 (Finberg and Rabey, 2016). α-Syn selectively combines with 
MAO-B and activates its enzymatic activity (Zhang et al., 2017). MAO-B catalyzes 
DA and produces metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL), which is 
highly toxic and can lead to oligomerization of α-Syn through covalent 
modifications of lysine residues (Plotegher et al., 2017). Besides, DOPAL can 
activates asparagine endopeptidase (AEP) and then AEP cleaves human a-Syn at N103. 
a-Syn N103 fragment has a stronger affinity with MAO-B than α-Syn and thus causes 
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abnormal DA metabolism by MAO ‐ B (Kang et al., 2018). Furthermore, the 
oligomerization of α-Syn can cause synaptic vesicle damage and DA leak (Plotegher 
et al., 2017, Post et al., 2018). After the released DA is converted to DOPAL by MAO-
B in dopaminergic neurons, DOPAL would induce a vicious cycle that further 
facilitating the oligomerization of α-Syn and causing synaptic impairment (Plotegher 
et al., 2017). The molecular interactions between MAO-B, α-Syn, AEP, and DOPAL 
were illustrated in Figure 1.1. 
Mitochondrial dysfunction is considered as another key event to provoke 
neurodegeneration (Schapira et al., 2007). It directly causes cell apoptosis or cause 
ATP depletion and oxidative stress, which may trigger cell apoptosis (Subramaniam 
and Chesselet, 2013). Mitochondrial respiration can consume almost all oxygen and 
oxidants are produced as byproduct in this process (Subramaniam and Chesselet, 2013). 
In PD patients or in drug-induced PD model, the complex I is inhibited and 
consequently the mitochondrial electron transport chain is blocked, which can largely 
increase the production of superoxide (Gubellini and Kachidian, 2015). The excess 
superoxide may react with lipids, proteins, DNA, and mitochondrial resulting in cell 
damage and cause further mitochondrial dysfunction (Gubellini and Kachidian, 2015). 
Because the DA metabolism process can produce large amount of superoxide radicals 
and hydrogen peroxide (H2O2), dopaminergic neuron itself is a fertile environment for 
ROS accumulation (Zeng et al., 2018). The vesicular storage of DA may be disrupted 
due to mitochondria-related ATP depletion and then DA leaks into cytoplasm and 
involves in producing ROS (Zeng et al., 2018). Therefore, DA plays a crucial role in 
increasing the susceptibility of SNc dopaminergic neurons to oxidative attack (Zeng 
et al., 2018).  
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Adapted from Kang et al., 2018 
Figure 1.1 Molecular interactions between MAO-B, α-Syn, AEP, and DOPAL. 
Schematic model for AEP-cleaved a-Syn N103 triggering MAO-B activation that 
feeds forward to further activate AEP by DA metabolite DOPAL.  
1.1.2(b) Disordered innate and adaptive immunity 
Although the pathogenesis of PD is not completely revealed, mounting 
evidences prove that the dysregulation of immune system including innate and 
adaptive immunity plays essential roles in the pathogenesis of PD (Chen et al., 2018). 
Microglia cells are a predominant type of resident immune cells in the brain 
(Gelders et al., 2018, Song and Colonna, 2018). They account for about 20% of total 
glia cells and play an important role in immune surveillance and central nervous 
system homeostasis (Smith et al., 2012). Microglia cells are found in two forms: 
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resting and activated forms (Smith et al., 2012). The resting microglia cells have long 
branching processes and small cellular body, and are termed ramified microglia cells 
(Song and Colonna, 2018). During development, they are involved in synaptic pruning 
in the thalamus, cerebellum and hippocampus (Smith et al., 2012, Song and Colonna, 
2018). They are responsible for removing normally occurring apoptotic neurons by 
efferocytosis (Song and Colonna, 2018). Furthermore, they can release low level 
neurotropic factors to support neurons and glia cells survival (Song and Colonna, 
2018). When the central nervous system (CNS) is infected by pathogens or in presence 
of tissue damage, ramified microglia cells undergo a series of changes in morphology, 
gene expression and function, and become activated (Huang and Halliday, 2012). The 
cell processes of activated microglial cells disappear and present ameboid morphology 
(Smith et al., 2012). After activation, microglia can be divided into M1 state and M2 
state (Huang and Halliday, 2012, Kannarkat et al., 2013). Microglia in the M2 state 
can release anti-inflammatory cytokines, such as interleukin-4 (IL-4) and interleukin-
13 (IL-13) , engulf damaged neuron fragments, and promote tissue repair and neurons 
regeneration (Gendelman and Mosley, 2015, Olson and Gendelman, 2016). But when 
microglia cells are over-activated, they turn to the M1 state and release a large number 
of neuroinflammatory cytokines such as tumor necrosis factor (TNF-α), interleukin-
1β (IL-1β), interleukin-6 (IL-6) by activating MAPKs/NF-κB/ERK pathway and lead 
to neurons apoptosis (Gendelman and Mosley, 2015, Olson and Gendelman, 2016). 
Microglia cells have a close relationship with the progress of PD (Song and Colonna, 
2018). Excessive ROS and activated M1 type microglia cells were found in 
postmortem of PD patients (Song and Colonna, 2018). In 6-hydroxydopamine (6-
OHDA) induced PD rats, M2 phenotype microglia increased in the first three days 
after drug treatment, then gradually decreased and shifted to M1 phenotype at later 
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time points, when dopaminergic neurons death was manifest (Ambrosi et al., 2017). 
Therefore, prevention microglia polarization to M1 phenotype may be a target for 
prevention and treatment of PD.  
Accumulating evidences have shown the adaptive immune system especially 
the various T lymphocytes are closely related with the progression of PD (Gelders et 
al., 2018). Total lymphocyte numbers are reduced in PD patients compared to healthy 
people (Bas et al., 2001, Baba et al., 2005). The absolute value and percentage of CD4+ 
CD25+ activated T cells are increased in PD patients. Meanwhile the number of naïve 
subset T cells (CD4+CD45RA+), helper T cells (CD4+), and memory helper T cells 
(CD4+CD29+) are all decreased (Bas et al., 2001). Suppressor/cytotoxic T cells (CD8+) 
remained unchanged (Bas et al., 2001). In its counterpart, the number of T-reg cells in 
peripheral blood were reported to be lower in PD patients and in 6-OHDA-induced PD 
animal model (Baba et al., 2005, Ambrosi et al., 2017). Besides, the number of CD8+ 
cells were reported to be higher in PD patients (Baba et al., 2005). T helper 1/17 
(Th1/17) cells are subsets of CD4+ T-lymphocytes and are responsible for regulating 
pro-inflammatory response playing a crucial part in many inflammatory diseases (Liu 
et al., 2017, Kustrimovic et al., 2018). In the peripheral blood of PD patients, naive T 
cells (CD4+) are inclined to differentiate into Th1 lineage (Kustrimovic et al., 2018). 
In peripheral blood, the number of Th17 cells of PD patients was much higher 
compared to healthy people (Chen et al., 2017). In drug-induced acute PD mice, Th17 
cells were found to traverse the lesioned brain-blood barrier (BBB) and reach 
substantial nigra of brain and cause inflammation by promoting glial activation (Liu 
et al., 2017). However, peripheral immunity also can play a positive action to decrease 
inflammation. For example, in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) induced acute PD model, pro-inflammatory Th1 cells were reduced, while 
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anti-inflammatory T-reg cells were elevated in the lymphoid tissue (Huang et al., 2014). 
Different stages of PD patients or animal models, different model induction drugs and 
administration methods may contribute to different results. In summary, the peripheral 
adaptive immunity is associated with the pathogenesis of PD. Targeting the adaptive 
immunoregulation especially T cell response maybe a therapeutic strategy in PD (Chen 
et al., 2018). 
1.1.3 Model systems in the study of PD 
1.1.3(a) Cell level models 
For cell level model, experimental conditions are easy to be controlled and 
operated and it is economic and efficient to construct a cell level model. Primary 
mesencephalic neurons, human neuroblastoma (SH-SY5Y) cell line and 
pheochromocytoma cell line (PC12) are widely used cells for constructing PD models 
(Falkenburger et al., 2016). When the cells are exposed to neurotoxins such as, 6-
OHDA, MPTP, paraquate or rotenone, they can mimic many characters observed in 
PD, such as reactive oxygen species (ROS) generation, inflammation, and neuron 
apoptosis (Beal et al., 2001, Xie et al., 2010). 
Since one of the typical characters of PD is the loss of mesencephalic DA 
neurons, human primary mesencephalic neurons are an ideal cell type for model 
establishment (Falkenburger et al., 2016). However, primary neurons of human source 
are quite difficult to be obtained, cultured, and handled and there exist ethical issues, 
which limits the application of this cell type (Beal et al., 2001, Schüle et al., 2011).  
SH-SY5Y is a neuronal tumor cell line, which was initially established from a 
neuroblastoma patient (Schüle et al., 2011). It can be cultured for a long period in vitro 
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without contamination, providing an unlimited supply of human origin cells (Lopes et 
al., 2010, Xie et al., 2010). SH-SY5Y cells have classic features of DA neurons, such 
as possessing tyrosine and dopamine-β-hydroxylases enzyme activity to synthesize 
DA and norepinephrine (Xie et al., 2010, Xicoy et al., 2017). They can express DA 
transporter (DAT), by which 1-methyl-4-phenylpyridinium (MPP+) can enter into 
neurons (Xie et al., 2010). Therefore, SH-SY5Y has been extensively applied to study 
the pathogenesis and mechanisms of MPP+-induced cytotoxicity and to study the 
potential compounds, which can attenuate the cytotoxicity (Xicoy et al., 2017). 
Additionally, SH-SY5Y cells can pre-differentiated into more pronounced DA neuron 
phenotype by various agents, such as retinoic acid (Beal et al., 2001, Xie et al., 2010). 
All these characters of SH-SY5Y cells make it a very useful tool to study the 
mechanisms of PD.  
1.1.3(b) Organotypic slice level models 
Cell level and animal level models have been well developed to be used for 
physiological and pathological studies, but both of them inevitably have defects (Kim 
et al., 2013, Schommer et al., 2017). Experimental conditions are easy to control in 
vitro, but cells cultured in vitro lose connection with other kinds of cells in tissue as 
well as some related biochemical characteristics (Schommer et al., 2017). Although 
animal models can obtain the overall pathophysiological response, the manipulation 
of experimental conditions is very limited, and it is difficult to analyze a single factor 
due to the influence of multiple factors in vivo (Kim et al., 2013). Organotypic slice 
culture is a platform established between cell culture and animal model and it could 
remedy disadvantages of single cell culture and animal studies (Mewes et al., 2012, 
Schommer et al., 2017). The cultured organotypic brain slices preserve structural and 
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synaptic organization of brain tissue and keep complex three dimensions neuronal 
network intact (Humpel et al., 2015). Additionally, decades of slices can be obtained 
from one brain, which allows repetitive experiments and excludes the influences by 
variations in individual animal (Kim et al., 2013). Thus, organotypic slice cultures 
provide a more efficient and reliable ex vivo platform to study the molecular and 
cellular mechanisms underlying the pathology of neurological disease and to evaluate 
potential therapeutic treatments for such diseases (Humpel et al., 2015).  
Different tissue-derived brain slices have been applied in neuroscience 
research (Tan et al., 2018), such as hippocampus region (Daviaud et al., 2013, Kim et 
al., 2013, Schommer et al., 2017), mesencephalon (Shen et al., 2010, McCaughey-
Chapman and Connor, 2017, de Araujo et al., 2018), Str (Kress and Reynolds, 2005, 
Sin et al., 2008, Shen et al., 2010), and cortex (Kress and Reynolds, 2005). Among all 
cultures, organotypic cultures from the ventral mesencephalon (VM) area are widely 
used to model PD by adding various neurotoxins in the medium to induce 
dopaminergic neurons death (Stahl et al., 2009). Keiko et al used the neurotoxin 
paraquat to establish a PD model at mesencephalon slice level and studied the 
protective function of several substances, such as inhibitors of nitric oxide synthase 
and DA D2/3 agonists (Shimizu et al., 2003). Dopaminergic neurons in 
mesencephalon-striatum slices co-culture was demonstrated to be more resistant to 
cytotoxicity than dopaminergic neurons in single mesencephalon slice cultures 
(Katsuki et al., 2001). Stahl et al devised a new technology to introduce neurotoxins 
6-OHDA to SN region of unilateral mesencephalon slice by means of microelectrode, 
which could mimic in vivo stereotactic models (Stahl et al., 2009). Furthermore, the 
contralateral side of slice serves as internal controls thus avoiding variation among 
different slices (Stahl et al., 2009). Worthy to mention, Daviaud and his group have 
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developed a sagittal organotypic slice containing complete nigrostriatal pathway, 
which was composed of SN, medial forebrain bundle (MFB) and Str areas. 
Subsequently, progressive nigrostriatal degeneration was induced without using any 
neurotoxins, only by mechanical transection of MFB while preparing the slices 
(Daviaud et al., 2014). 
In conclusion, ex vivo organotypic slice cultures provide a promising platform 
for neuroscience research and can contribute to neurodevelopment (McCaughey-
Chapman and Connor, 2017), electrophysiology (Wang et al., 2015), pathology 
mechanisms of brain disorders, such as neurodegenerative disease (McCaughey-
Chapman and Connor, 2017), demyelination (Tan et al., 2018) and ischemia (Humpel 
et al., 2015), and to study potential therapeutic compounds/cells for diseases (Qi et al., 
2019). 
1.1.3(c) Toxin-induced animal models  
Although PD animal models can not accurately recapitulate all aspects of 
human diseases, they have become quite useful tools to assess the effects of new 
pharmacological therapies, gene therapies and cell transplantation. In this chapter, 
several widely used neurotoxins to generate PD models are introduced. These 
neurotoxins include MPTP, 6-OHDA, paraquat (N, N-dimethyl-4-4-bipiridinium) and 
rotenone, which have received the most attention (Terzioglu and Galter, 2008).   
MPTP was discovered in 1982 and it is the only neurotoxin that can mimic 
human parkinsonism (Gubellini and Kachidian, 2015). Thus, it became the most 
common used drug to induce PD model (Gubellini and Kachidian, 2015). It is highly 
lipophilic and can penetrate the BBB within minutes (Dauer and Przedborski, 2003, 
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Blesa et al., 2012). For the ability to become toxic, MPTP must be converted to MPP+ 
in glia cells and serotonergic neurons by MAO-B (Gubellini and Kachidian, 2015). 
After released into the extracellular compartment by unknown mechanisms, MPP+ can 
enter dopaminergic neurons with DAT-dependent manner and accumulate in the 
mitochondria (Gubellini and Kachidian, 2015). It can block electron transport chain 
by inhibiting complex I and impair oxidative phosphorylation process, thereby causing 
energy crisis and ROS accumulation, finally inducing apoptosis of dopaminergic 
neurons (Schober et al., 2004, Gubellini and Kachidian, 2015, Yun et al., 2015, 
Schirinzi et al., 2016). MPTP induced PD model is already successfully done in 
primates, rodents, sheep, dogs, frogs, and invertebrates such as leech and planarian 
(Shimohama et al., 2003, Yun et al., 2015). Primates are more sensitive to MPTP than 
rodents (Zeng et al., 2018). However, the pathology is different from human PD 
because there is no typical LBs generation and there is no consistent neurons lost from 
other monoaminergic nuclei in MPTP-induced PD models (Gubellini and Kachidian, 
2015). Although the MPTP induced models are not as perfect to mimic human PD 
pathologies, they are now the gold standard for assessment of novel strategies and 
agents for the treatment of PD (Schirinzi et al., 2016, Zeng et al., 2018). 
The agent of 6-OHDA is the first drug applied to construct PD models since 
late 1960s (Emborg et al., 2004, Uversky et al., 2004, Gubellini and Kachidian, 2015). 
Different from MPTP, this neurotoxin cannot pass through the BBB and it should be 
administered into brain by stereotaxic apparatus whilst the preferred injection sites are 
substantia nigra, median forebrain bundle or Str (Emborg et al., 2004, Schober et al., 
2004, Gubellini and Kachidian, 2015, Yun et al., 2015, Schirinzi et al., 2016). Only 
neonatal animals whose blood BBB is immature can be affected by systemic 
administration of 6-OHDA (Emborg et al., 2004). It has been proven to be an effective 
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toxin in primates, rodents, dogs and cats (Shimohama et al., 2003, Tieu et al., 2011, 
Gubellini and Kachidian, 2015). After injected with 6-OHDA, animals manifest with 
an asymmetric circling behavior and the dose of drug decides the extent of the 
nigrostriatal lesion and the magnitude of asymmetric circling behavior. Because the 
lesion size and abnormal motor function can be quantitatively assayed, this kind of 
models is quite useful to assess the function of new drugs or new cell and gene therapy 
(Shimohama et al., 2003, Tieu et al., 2011). However, different from human PD, none 
of these animal models have LBs formation in the SNc region and the damage of 6-
OHDA to dopaminergic neurons is nonspecific (Tieu et al., 2011). Besides, like many 
other drug-based PD models, acute PD models induced by 6-OHDA lack age-related 
and progressive characters of PD patients (Tieu et al., 2011). 
Paraquat is an organic compound widely used in agriculture as herbicide and 
is also called N, N′-dimethyl-4,4′-bipyridinium dichloride (Cheng et al., 2018). It is 
not only poisonous to green plants but also hypertoxic to human and animals and there 
is no antidotes against paraquat poisoning (Suntres et al., 2018). Although similar 
structure to MPP+, paraquat is not as easy to pass through BBB as MPP+ and rely on 
neutral amino acid transporter (Dauer and Przedborski, 2003, Zeng et al., 2018). The 
toxicity mechanisms between paraquat and MPP+ are dissimilar (Tieu et al., 2011). 
Firstly, paraquat is not substrate of DAT and how paraquat enter dopaminergic neurons 
is unknown (Tieu et al., 2011). Besides, paraquat induces ROS mainly mediated by 
redox cycling with nitric oxide synthase and NADPH oxidase (Tieu et al., 2011). 
Furthermore, different from MPTP, paraquat is not an inhibitor of complex I of the 
electron transport chain inside mitochondrial (Zeng et al., 2018). It is closely related 
to the development of PD, because it can cause dopaminergic neuron loss and α-
synuclein contained inclusions after administration to mice (Vaccari et al., 2017). 
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Paraquat is useful to clarify the relationship between α-synuclein aggregation and the 
development of PD. However, paraquat cannot significantly induce DA depletion in 
striatal and motor dysfunction, which may limit the use of this drug (Tieu et al., 2011). 
Rotenone is extracted from the roots of tropical plants as a kind of natural 
pesticide (Gubellini and Kachidian, 2015). It can readily enter into all cells because of 
highly lipophilic character (Gubellini and Kachidian, 2015). After entering 
mitochondrial, rotenone blocks mitochondrial respiration chain by specifically 
inhibition the activity of complex I and the binding site with mitochondrial complex I 
is the same with MPP+ (Dauer and Przedborski, 2003, Gubellini and Kachidian, 2015, 
Yun et al., 2015, Schirinzi et al., 2016). When rats were systemically and chronically 
exposed to rotenone by intravenous injection, it resulted in LBs formation, nigrostriatal 
pathway damage, and clinical manifest of PD, such as postural instability and tremor 
(Zeng et al., 2018). Therefore, this neurotoxin may enable researchers to clarify the 
relationship between apoptosis of dopaminergic neurons and LBs formation (Gubellini 
and Kachidian, 2015). However, the nigrostriatal pathway damages induced by 
rotenone are not consistent and this drug can cause high mortality rate of animals 
(Betarbet et al., 2000, Gubellini and Kachidian, 2015).  
1.2 Current Treatment for PD 
Pharmacological and surgery are two common treatments to relieve symptoms 
of PD (Bezard et al., 2001, Yasuhara et al., 2015). Because the impaired motor function 
of PD is related to the DA depletion in the Str region, symptomatic treatment helps to 
restore neurotransmitter DA level by administration medicines, such as L-3,4-
dihydroxyphenyl-alanine (L-DOPA) and DA agonists (Braak et al., 2003). Although 
PD symptoms are relieved by L-DOPA increasing DA administration, it brings drug-
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induced side effects, such as motor fluctuations and dyskinesia and it cannot retard or 
reverse the progressive degeneration of dopaminergic neurons (Bezard et al., 2001, 
Yasuhara et al., 2015). Furthermore, the efficacy of treatment become lower and lower 
as the disease progresses and new clinical manifests occur, among which some 
symptoms even fail to respond to medicines (Braak et al., 2003, Langston et  al., 
2006). DA agonists, such as rotigotine, pramipexole, and ropinirole, which can activate 
DA receptors and relieve motor dysfunction (Ceravolo et al., 2016). The adverse 
effects of DA agonist include both peripheral and central events such as orthostatic 
hypotension, gastrointestinal disease, psychosis, and hallucinations, which limit their 
long-term using (Bonuccelli and Ceravolo, 2008). 
In addition to increasing DA level, two types of medications have been 
administrated to utilize existing DA more effectively. One type is catechol-O-
methyltransferase (COMT) inhibitors (Finberg and Rabey, 2016). COMT inhibitors, 
such as tolcapone and entacapone, can block the breakdown of levodopa and thus more 
levodopa can reach brain and convert to DA by dopa decarboxylase (Waters, 2000). 
Another type is MAO-B inhibitors (Finberg and Rabey, 2016). Monoamine oxidase 
(MAO) is a kind of enzyme, which catalyzes the oxidative deamination of monoamine 
substances, such as DA, and produces aldehydes and H2O2 (Finberg and Rabey, 2016). 
MAO has two isoforms MAO-A (monoamine oxidase type A) and MAO-B, which can 
be differentiated by their inhibitor specificities and substrate (Riederer and Laux, 2011). 
Clorgyline and moclobemide are inhibitors of MAO-A. The inhibition of MAO-A 
increases noradrenaline level in noradrenergic neurons and serotonin level in 
serotonergic neurons, which has antidepressant function (Finberg, 2014, Finberg and 
Rabey, 2016). MAO-B inhibitors, such as selegiline, rasagiline, and safinamide can 
improve dyskinesia, reduce off-time and delay the need for levodopa, which are used 
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as anti-Parkinson drug (Cereda et al., 2017, Dézsi and Vécsei, 2017). Some 
compounds combining symptomatic DA treatments with COMT or MAO-B inhibitors 
have been investigated aiming to enhance the long-term effect for PD patients 
(Nomoto et al., 2003, Schapira and Olanow, 2004). However, none has fulfilled the 
requirements of preventing PD progression (Nomoto et al., 2003, Schapira and 
Olanow, 2004). The pharmocological treatment of PD was summarized in Figure 1.2. 
Surgery includes deep brain stimulation of subthalamic nucleus, mutilation of 
globus pallidum interna or ventral intermediate thalamic, which are performed when 
medications do not work and have been proved to improve motor function and quality 
of life (Videnovic and Metman, 2008, Rowland et al., 2015). However, complications 
would occur after surgery, such as worsening verbal fluency, cerebral hemorrhage, 
sensory disturbance, visual field defect, and dysphagia, which may bring another big 
burden to patients (Højlund et al., 2016, Weinkle et al., 2018). 
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Cited from Church F. 2017 
Figure 1.2 Pharmocological treatment of PD. This figure is cited from (Church F. 2017, 
March 20). In dopaminergic neurons, L-tyrosine is converted to L-dopa under 
catalization of tyrosine hydroxylase. Then L-dopa is converted to dopamine by dopa 
decarboxylase. After dopamine is reseased from presynaptic membrane, it enters 
receiving cells by dopamine receptors or is metabolized by MAO-B and COMT. So, 
four kinds of drugs can be used to increase dopamine level: L-dopa, MAO-B inhibitors, 
COMT inhibitors, and dopamine agonists. 
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1.3 Cell-based Therapies for PD 
1.3.1 Stem cell classification  
Stem cells are undifferentiated or unspecialized cells, which can differentiate 
into various specialized cell types and self-renew (Lazic and Barker, 2003). According 
to their differentiation ability, they can be classified into totipotent, pluripotent and 
multipotent stem cells and different cell types have specific sources (Lazic and Barker, 
2003, Wenker et al., 2015). Totipotent stem cells refer to fertilized zygote and all cells 
within 16-cell stage, which has the ability to form all cell types. Pluripotent stem cells 
include two types: embryonic stem cells (ESCs) and induced pluripotent stem cells 
(iPSCs) (Wenker et al., 2015). ESCs can be collected from inner cell mass at blastocyst 
stage of embryonic development. They can differentiate into nearly all cell lineages 
except for trophoblast cells which can form fetal membrane and placenta later (Lazic 
and Barker, 2003, Parish and Arenas, 2007, Fu et al., 2015). iPSCs, also called ES-like 
cell, are derived from somatic cells such as fibroblasts by transfecting some self-
renewal and pluripotent factors to make somatic cells de-differentiation (Fu et al., 2015, 
Goodarzi et al., 2015, Wenker et al., 2015). The successful generation of iPSCs was 
first reported by Kazutoshi Takahashi and Shinya Yamanaka in 2006 by lentiviral 
expression of four transcription factors in mouse embryonic fibroblasts including 
cellular myelocytomatosis (c-Myc), kruppel-like factor 4 (Klf 4), octamer-binding 
transcription factor 3/4 (Oct3/4), and sex determining region Y-box 2 (Sox2) 
(Takahashi and Yamanaka, 2006). Multipotent stem cells are derived from fetal or 
adult tissues and they can differentiate into tissue-specific progeny. Neural stem cells 
(NSCs) and mesenchymal stem cells (MSCs) both belong to this type of cells (Lazic 
and Barker, 2003, Parish and Arenas, 2007, Fu et al., 2015). Human NSCs were first 
reported in 1965 and they can be isolated from fetal brain, hippocampus, 
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subventricular zone of adult brain, and ESCs (Han et al., 2015, Zhu et al., 2016). They 
have potential to differentiate into different kinds of neurons, astrocytes and 
oligodendrocytes (Parish and Arenas, 2007, Han et al., 2015, Zhu et al., 2016). Bone 
marrow-derived mesenchymal stem cells (BM-MSCs) were the first kind of MSCs to 
be reported and so far, MSCs have been shown also exist in umbilical cord, umbilical 
cord blood, Wharton’s jelly, adipose, placenta, endometrium, menstrual blood, dental 
tissues, amniotic fluid and etc. (Kögler et al., 2004, Patel et al., 2008, Ullah et al., 
2015). They are negative for HLA-DR, CD11b, CD14, CD19, CD34, and CD 45 and 
meanwhile positive for CD73, CD 90 and CD105 (Horwitz et al., 2005, Salem and 
Thiemermann, 2010, Ullah et al., 2015). They have multi-differentiation ability in vitro, 
such as chondrogenesis, adipogenesis, osteogenesis, neurogenesis, and cardiogenesis 
(Patel et al., 2008, Salem and Thiemermann, 2010, Zemelko et al., 2013, Ullah et al., 
2015).  
1.3.2 Menstrual blood-derived endometrium stem cells (MenSCs)  
Menstrual blood-derived endometrium stem cells (MenSCs) were firstly 
reported in 2007, which were isolated from menstrual blood (Meng et al., 2007, Cui 
et al., 2007). Until now, there is still no uniform name for this kind of stem cells. Chen 
et al. summarized all the existing 12 nomenclatures in their review paper (Chen et al., 
2019). In this thesis, MenSCs was used throughout.  
The doubling time of MenSCs is about 19.5 hrs, which is less than umbilical 
cord-derived MSCs (UC-MSCs, 36 hrs-48 hrs) (Meng et al., 2007) and bone marrow-
derived MSCs (BM-MSCs, 40 hrs-45 hrs) (Wu et al., 2014). They were reported to 
expand up to 68 doublings with normal karyotype and sustained surface markers 
(Meng et al., 2007). While other researchers showed they would stop proliferation 
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before 30 doublings (Cui et al., 2007). The proliferation speed of MenSCs is negatively 
correlated with the age of the donors and the cell passage (Liu et al., 2018). Because 
Meng and Cui did not mention the donors age of the menstrual blood samples, the 
different result of the ability of doubling times maybe was due to different age of 
donors. Besides, the different components of medium they used maybe another 
important reason. MenSCs were able to differentiate into three germ layers: ectoderm 
(neurons), mesoderm (adipocyte, osteocyte, myocyte, cardiomyocyte endothelium) 
and endoderm (hepatocyte, pancreatic cells, respiratory epithelium) in vitro (Meng et 
al., 2007). MenSCs share similar morphology and some surface markers with other 
sources MSCs, such as positive for CD29, CD73, CD90, CD105 and negative for 
CD14, CD19, CD34, and CD45. The unique characters of MenSCs are the expression 
of ESCs marker OCT-4, positive for human telomerase reverse transcriptase, lack of 
STRO-1 expression, and different secreted factors (Meng et al., 2007).  
Since the discovery of MenSCs, they have been used for therapy of various 
diseases in lab, such as stroke (Borlongan et al., 2010), type I diabetes (Wu et al., 
2014), hepatic failure (Chen et al., 2017), premature ovarian failure (Wang et al., 2017), 
liver fibrosis (Chen et al., 2017), lung injury (Xiang et al., 2017), and cardiac diseases 
(Liu et al., 2019). One clinical study showed that MenSCs were intravenously and 
intrathecally administrated to multiple sclerosis patients and no adverse effects or 
immune rejection were observed in one-year follow-up, which indicated the feasibility 
of clinical use (Zhong et al., 2009). After co-culture MenSCs with rat primary neurons 
exposed to oxygen and glucose deprivation, MenSCs significantly promoted neurons 
survival by releasing vascular endothelial growth factor, brain-derived neurotrophic 
factor (BDNF), and neurotrophin-3 (NT-3) (Borlongan et al., 2010). MenSCs 
improved liver function after transplanted to liver fibrosis mouse model by inhibiting 
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activated hepatic stellate cells. Moreover, in vitro co-culture experiment showed 
MenSCs inhibited the proliferation of activated hepatic stellate cells by secretion of 
monocyte chemoattractant protein-1, IL-6, interleukin-8 (IL-8), hepatocyte growth 
factor (HGF) and so on (Chen et al., 2017). The transplantation of MenSCs decreased 
the expression of pro-inflammatory cytokines IL-1β and IL-6 and increased the 
expression of anti-inflammatory cytokines interleukin-10 (IL-10) and transforming 
growth factor-β (TGF-β) in lipopolysaccharide-induced acute lung injury mouse 
model (Xiang et al., 2017). MenSCs-derived exosomes (MenSCs-Exo) was shown to 
inhibit apoptosis of hepatocyte in fulminant hepatic failure mouse model and decrease 
the expression of pro-inflammatory cytokines, such as IL-1β, IL-6 and TNF-α after co-
culture with lipopolysaccharide-induced AML12 hepatocyte cell line (Chen et al., 
2017). Neuroinflammation and dopaminergic neurons loss played an important role in 
the pathogenesis of PD (Zeng et al., 2018). Although MenSCs and MenSCs-Exo 
showed protective function in lung or liver disease by anti-apoptosis and 
immunomodulation, it is unknown whether they have therapeutic effect on PD by 
promoting neurons survival and regulating inflammatory cytokines expression. This 
question will be answered in this study. 
1.3.3 Cell types used in the treatment of PD  
Since the clinical manifests of PD are mainly caused by malfunction of 
dopaminergic neurons, theoretically, stem cells which can differentiate into 
dopaminergic neurons can be used for transplantation to provide exogenous 
dopaminergic neurons to restore the DA abnormalities (Politis and Lindvall, 2012, Yue 
and Jing, 2015). There are four kinds of stem cell types commonly used for cell therapy 
to treat PD: ESCs, iPSCs, NSCs, and MSCs (Lindvall et al., 2004, Politis and Lindvall, 
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2012, Fu et al., 2015, Goodarzi et al., 2015).  
Compared to the limited differentiation potential of NSCs and MSCs, ESCs 
and iPSCs can differentiate into unlimited DA neurons (Fu et al., 2015, Goodarzi et 
al., 2015). However, there are many disadvantages of using ESCs and iPSCs. ESCs 
are prone to generate into tumors, major ethic issues are involved, and it is difficult to 
obtain quality oocytes (Fu et al., 2015, Goodarzi et al., 2015). As for iPSCs, the 
genomic stability is still questionable and some factors used for reprogramming or 
viral vectors integrated into genome can increase the risk of tumorigenesis (Fu et al., 
2015, Goodarzi et al., 2015, Yasuhara et al., 2015, Zhu et al., 2016). NSCs can be 
derived from fetal brain and adult brain mainly in subventricular zone and 
hippocampus (Zhu et al., 2016). Although the tumorigenesis risk of NSCs is lower 
than ESCs and iPSCs, the source is quite limited and there exists ethical issues. Besides, 
it cannot realize autologous transplantation (Goodarzi et al., 2015). Compared to ESCs 
and iPSCs, which allows almost all lineages differentiation, the differentiation and re-
newal ability of the MSCs is much lower, but they are genetically more stable, readily 
available from extensive sources, more easily isolated, cultured and expanded and no 
major ethical issues (Levy et al., 2015, Ullah et al., 2015). Besides, MSCs have low 
immunogenic properties due to the lack of MHC-II, so that they can undergo allograft 
with low immunological rejection risks (Fu et al., 2015, Goodarzi et al., 2015, Zhu et 
al., 2016).  
1.3.4 The therapeutic potential of MSCs on PD animal models 
Ove the last decade, bone marrow-derived MSCs (BM-MSCs) have become 
the most widely used cell to treat PD animals induced by neurotoxins, such as MPTP 
and 6-OHDA (Li et al., 2001, Lu et al., 2005, Hellmann et al., 2006, Ye et al., 2007, 
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Levy et al., 2008, Campeau et al., 2014). BM-MSCs were shown to survive in Str 
region of PD mice brain, differentiate to dopaminergic neurons expressing tyrosine 
hydroxylase (TH) and improve animal motor function (Li et al., 2001). The similar 
results were observed in umbilical cord-derived MSCs (UC-MSCs) transplanted PD 
mice induced by 6-OHDA (Kang et al., 2013). Hellmann et al. constructed a PD model 
by unilateral 6-OHDA stereotaxic injection and the same number of BM-MSCs were 
transplanted into both sides of brain. Results showed that there were more cells 
survived in 6-OHDA lesioned side of hemisphere than contralateral unlesioned side, 
which indicated that different microenvironment would affect the survival of engrafted 
MSCs (Hellmann et al., 2006). Besides, after transplanted to healthy side of cerebral 
hemisphere, BM-MSCs can migrate to the lesioned side (Hellmann et al., 2006). TH 
or neuturin overexpressed BM-MSCs were also tried to achieve better effect than naïve 
cells. Results showed they could significantly increase DA level in the damaged Str 
region and improve motor function of PD rat model (Lu et al., 2005, Ye et al., 2007). 
Additionally, Ye et al. showed that gene modified BM-MSCs achieved better 
therapeutic effect than naïve cells (Ye et al., 2007). Although MSCs can be pre-
differentiated into neuron-like cells in vitro detected by surface markers of neurons, 
it’s largely unknown whether the differentiated MSCs can interact with local neurons 
and establish neuron network after graft and whether neuron differentiation is 
necessary to achieve better therapeutic effect (Jeong et al., 2004, Ning et al., 2006, 
Levy et al., 2008, Barzilay et al., 2009, Wolff et al., 2011, Guan et al., 2014). In vitro 
neuron-induced and naïve adipose-derived MSCs (AD-MSCs) were transplanted into 
SN region of PD rat model separately (McCoy et al., 2008). Results demonstrated 
these two kinds of grafts can protect dopaminergic neurons survival, which indicates 
that in vitro neural induction before transplantation are not necessary for AD-MSCs to 
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exert neuroprotective effects (McCoy et al., 2008). Furthermore, AD-MSCs derived 
neurotrophic factors and cytokines known to promote dopaminergic neurons survival 
at the lesion site, which may have contributed to the therapeutic effect of AD-MSCs 
transplantation (McCoy et al., 2008). On the contrary, Levy et al. reported that grafting 
BM-MSCs derived neuron-like cells can ameliorate rotation behavior while naïve BM-
MSCs or PBS injected rats did not show a statistically significant reduction in rotations, 
which proved neural induction of the BM-MSC prior to transplantation had a 
significant advantage over naive BM-MSCs (Levy et al., 2008). Whether pre-
transplanting differentiation is necessary need further study and more evidence. 
Endometrium-derived stem cells (EDSCs), which can be obtained from endometrium, 
were used to generate dopaminergic cells for transplantation. Wolff et al showed that 
EDSCs can be induced into dopaminergic neurons in vitro and can also differentiate 
into neuron-like cells in vivo (Wolff et al., 2011, Wolff et al., 2015). EDSCs could also 
migrate to the site of lesion, significantly increase DA and DA metabolite 
concentrations in the Str, and increase the numbers of TH positive cells in 
immunocompetent PD mouse or primate model (Wolff et al., 2011, Wolff et al., 2015). 
Most studies were focused on detecting DA or TH level and rotation function after 
naïve or induced cell transplantation, while Campeau et al. showed that the voiding 
function of PD rat was also improved after BM-MSCs graft. Non-microencapsulated 
group improved urodynamic pressure more markedly than the microencapsulated 
group and there were more TH positive neurons in non-microencapsulated group, 
which suggested functional improvement required the juxtracrine effect (Campeau et 
al., 2014). Kumar et al. investigated the therapeutic effect of fetal liver MSCs (FL-
MSCs) derived dopaminergic neuronal cells on PD. The results showed they can 
integrate into the Str of PD mice and improve PD symptoms, suggesting FL-MSCs is 
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also a promising tool for cell therapy (Kumar et al., 2016). Findings of research about 
MSCs for treatment of PD is summarized in Table 1.1. 
Naïve MSCs, modified MSCs and their derivatives as potential treatments for 
PD have received satisfactory results by cellular replacement or paracrine secretion 
(Sadan et al., 2009, Lindvall and Kokaia, 2010). However, some major obstacles need 
to be overcome before these findings can be translated into novel therapies for patients.  
Firstly, further studies need to be done about mechanisms to control stem cell 
migration, survival, proliferation, and differentiation in the pathological environment 
after grafting (Lindvall and Kokaia, 2010). Stereotaxic intracerebral transplantation is 
the only method to directly transplant MSCs into different regions of brain. The 
surgery is time-consuming, expensive, and cause some untoward effects. For example, 
there are hundreds of PD patients worldwide who had undergone human fetal 
mesencephalic stem cells striatal transplantation, and more than half show graft-
induced dyskinesias with only minimal cells that can survive and differentiate in the 
injected region (Lindvall and Björklund, 2004, Politis and Lindvall, 2012). Many 
groups have reported different tissue derived MSCs can survive in the brain, but the 
duration of survival and methods to increase their survival time needs further study (Li 
et al., 2001, Wu et al., 2007, Ye et al., 2007, Levy et al., 2008, McCoy et al., 2008, 
Salem et al., 2014). The survival time is closely related to the transplantation times 
and dose for patients. For cell replacement therapy, different cell types will be needed 
for different diseases. For example, PD requires dopaminergic neurons, amyotrophic 
lateral sclerosis (ALS) needs motor neurons, while Alzheimer’s disease (AD) demands 
several cell types to be effective (Lindvall and Kokaia, 2010). It’s difficult to control 
which direction the cell will differentiate to after transplantation. If the grafted cells 
